ESCMID Global 2025: Shionogi Presents Real-World Data Demonstrating Better Clinical Outcomes When Fetcroja® / Fetroja® (Cefiderocol) Is Used as Empiric or Documented Therapy as Compared To Salvage Therapy for the Treatment of Gram-Negative Bacterial Infections

Shionogi & Co., Ltd. presents new European data from its largest real-world evidence study of Fetroja^®/Fetcroja^® (cefiderocol), an innovative siderophore cephalosporin at the 35th Congress of the European Society of Clinical Microbiology and Infectious Diseases in Vienna on 11th–15th April 2025.